
(IN BRIEF) Merck and The Michael J. Fox Foundation (MJFF) are collaborating to advance Parkinson’s disease research using Merck’s SMCxPRO® immunoassay technology. This initiative aims to detect biomarkers indicating cell dysfunction in PD patients, enhancing research into new treatment options … Read the full press release